Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
NCT06908694
Recruiting
GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Juravinski Cancer Centre, Hamilton, Ontario
Conditions: Prostate Cancer
Register for Updates
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
NCT05669755
Active Not Recruiting
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected br... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/22/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +566 locations
Conditions: Cardiovascular Disease
Register for Updates
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
NCT06131372
Active Not Recruiting
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, se... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: John Muir Physicians Network, Concord, California +119 locations
Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity
Register for Updates
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869
Recruiting
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: eStudySite, La Mesa, California +49 locations
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Register for Updates
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III
NCT06097390
Completed
In this study, a known medicine called 'semaglutide' will be tested in two different tablet versions. The two tablets differ in the way these have been manufactured. The aim of the study is to investigate the amount of active ingredient in the blood after dosing the different tablet versions. Participants will receive one tablet version for 10 days (first treatment period) and the other version for 10 days (second treatment period). The treatment arm participants will be assigned to is decided b... Read More
Gender:
MALE
Ages:
Between 18 years and 64 years
Trial Updated:
07/15/2025
Locations: Altasciences Clinical Company, Inc, Montreal, Quebec
Conditions: Healthy Participants
Register for Updates
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
NCT06579105
Active Not Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
07/15/2025
Locations: Research Site, Mobile, Alabama +96 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
NCT05064735
Completed
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pain in the knee in people taking semaglutide with people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Pa... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/09/2025
Locations: Baptist Health System, Montgomery, Alabama +65 locations
Conditions: Obesity
Register for Updates
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
NCT05259033
Completed
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to semaglutide. Participants will either get IcoSema or semaglutide. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can alread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Univ of AL at Birmingham_BRM, Birmingham, Alabama +136 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
NCT04560998
Completed
This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo ("dummy") medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some countries. Participants will get the study medicine (semaglutide or placebo) in a pre-filled pen for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Angel City Research, Inc., Los Angeles, California +123 locations
Conditions: Diabetes Mellitus, Type 2, Peripheral Arterial Disease
Register for Updates
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449
Recruiting
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Valley Clinical Trials, Covina, California +36 locations
Conditions: Obesity
Register for Updates
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396
Active Not Recruiting
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/24/2025
Locations: Banner Alzheimer's Institute, Phoenix, Arizona +342 locations
Conditions: Early Alzheimer's Disease
Register for Updates
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409
Active Not Recruiting
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/24/2025
Locations: Banner Alzheimer's Institute, Phoenix, Arizona +389 locations
Conditions: Early Alzheimer´s Disease
Register for Updates